Esophagogastric Junction Cancer
Conditions
Brief summary
This is a non-interventional study to observe the safety and efficiency of chemotherapy for potentially resectable locally advanced esophagogastric junction
Interventions
None listed
Sponsors
Anyang Tumor Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytological proved locally advanced esophagogastric junction cancer * ECOG performance status ≦2 * Stage IIa-IIIc * No distant metastasis (M0) * Sign in Informed Consent Form
Exclusion criteria
* History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and Oteracil Potassium Capsules , capecitabine, oxaliplatin or the ingredients of this product * Pregnancy or lactation women, * Inadequate hematopoietic function： WBC≦3,500/mm3; ANC≦1,500/mm3; Platelet≦80,000/mm3 * Inadequate organ function which is defined as below: Total bilirubin \>2 pper limit of normal range (ULN); ALT / AST \> 2.5 upper limit of normal range (ULN); serum creatinine \> 1.5 mg/dL, and Ccr \> 60 ml/min (estimated by Cockcroft-Gault formulation); * Symptomatic peripheral neuropathy * Receiving a concomitant treatment with other fluoropyrimidines * Fluoropyrimidines (DPD) congenital absence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease free survival(DFS) | up to 3 years | time from surgery to disease recurrence or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | up to 5 years | time to death |
| Adverse events(AE) | through study completion, up to 1 year | Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 4.03. |
Countries
China
Contacts
Primary ContactLi Baozhong
Outcome results
None listed